Hartford Financial Management’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-266
| Closed | -$429 | – | 349 |
|
|
2025
Q1 | $429 | Hold |
266
| – | – | ﹤0.01% | 352 |
|
|
2024
Q4 | $336 | Hold |
266
| – | – | ﹤0.01% | 372 |
|
|
2024
Q3 | $501 | Hold |
266
| – | – | ﹤0.01% | 375 |
|
|
2024
Q2 | $1.97K | Hold |
266
| – | – | ﹤0.01% | 363 |
|
|
2024
Q1 | $2.08K | Hold |
266
| – | – | ﹤0.01% | 365 |
|
|
2023
Q4 | $1.35K | Sell |
266
-332
| -56% | -$1.71K | ﹤0.01% | 378 |
|
|
2023
Q3 | $3.54K | Hold |
598
| – | – | ﹤0.01% | 340 |
|
|
2023
Q2 | $4.44K | Hold |
598
| – | – | ﹤0.01% | 317 |
|
|
2023
Q1 | $5.65K | Hold |
598
| – | – | ﹤0.01% | 307 |
|
|
2022
Q4 | $6.37K | Hold |
598
| – | – | ﹤0.01% | 300 |
|
|
2022
Q3 | $4K | Hold |
598
| – | – | ﹤0.01% | 318 |
|
|
2022
Q2 | $3K | Hold |
598
| – | – | ﹤0.01% | 335 |
|
|
2022
Q1 | $3K | Hold |
598
| – | – | ﹤0.01% | 348 |
|
|
2021
Q4 | $4K | Hold |
598
| – | – | ﹤0.01% | 324 |
|
|
2021
Q3 | $5K | Hold |
598
| – | – | ﹤0.01% | 322 |
|
|
2021
Q2 | $5K | Hold |
598
| – | – | ﹤0.01% | 329 |
|
|
2021
Q1 | $5K | Hold |
598
| – | – | ﹤0.01% | 334 |
|
|
2020
Q4 | $5K | Hold |
598
| – | – | ﹤0.01% | 310 |
|
|
2020
Q3 | $6K | Sell |
598
-2
| -0.3% | -$22 | ﹤0.01% | 284 |
|
|
2020
Q2 | $6K | Hold |
600
| – | – | ﹤0.01% | 285 |
|
|
2020
Q1 | $3K | Hold |
600
| – | – | ﹤0.01% | 306 |
|
|
2019
Q4 | $4K | Hold |
600
| – | – | ﹤0.01% | 318 |
|
|
2019
Q3 | $4K | Hold |
600
| – | – | ﹤0.01% | 328 |
|
|
2019
Q2 | $4K | Hold |
600
| – | – | ﹤0.01% | 324 |
|
|
2019
Q1 | $9K | Hold |
600
| – | – | ﹤0.01% | 303 |
|
|
2018
Q4 | $7K | Hold |
600
| – | – | ﹤0.01% | 322 |
|
|
2018
Q3 | $13K | Hold |
600
| – | – | ﹤0.01% | 303 |
|
|
2018
Q2 | $12K | Hold |
600
| – | – | ﹤0.01% | 307 |
|
|
2018
Q1 | $6K | Hold |
600
| – | – | ﹤0.01% | 287 |
|
|
2017
Q4 | $11K | Hold |
600
| – | – | 0.01% | 261 |
|
|
2017
Q3 | $10K | Buy |
600
+367
| +158% | +$8.05K | 0.01% | 295 |
|
|
2017
Q2 | $8K | Hold |
233
| – | – | ﹤0.01% | 296 |
|
|
2017
Q1 | $10K | Hold |
233
| – | – | 0.01% | 262 |
|
|
2016
Q4 | $6K | Hold |
233
| – | – | ﹤0.01% | 267 |
|
|
2016
Q3 | $9K | Buy |
233
+166
| +248% | +$8.52K | 0.01% | 242 |
|
|
2016
Q2 | $3K | Buy |
+67
| New | +$3.74K | ﹤0.01% | 265 |
|
Other funds holding ATNM
GS
CFD
Hartford Financial Management's ATNM Position: Q2 2025 in Review
Hartford Financial Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 266 shares — an estimated $429 sold.
Hartford Financial Management first reported a position in ATNM in Q2 2016 and held it in 36 quarters. The position peaked at $13K in Q3 2018. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.
- Hartford Financial Management reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Hartford Financial Management sold 266 Actinium Pharmaceuticals shares in Q2 2025, an estimated $429.
- Hartford Financial Management first reported a position in Actinium Pharmaceuticals in Q2 2016 and held it in 36 quarters.
- Hartford Financial Management's Actinium Pharmaceuticals position peaked at $13K in Q3 2018.
- 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.
Based on Hartford Financial Management's 13F filing for Q2 2025, filed 31 Jul 2025.